亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

Vim3 Antibody

總結: Liquid biopsy: non-invasive test for preoperative diagnosis and differentiation of benign and malignant renal carcinoma

技術優勢: Novel approach: markers for non-invasive diagnosis of kidney Tumors
Optimized treatment and follow-up of patients due to an accurate and valid diagnosis and differentiation of benign kidney tumors and malignant renal carcinomas
Markers also usable for routine medical checkup (persons aged 55 and above)
Monoclonal antibodies designed for use
Urine quick test in development

技術應用: Detection of the markers in urine makes it possible for the first time to provide urologist and oncologist a non-invasive test for a preoperative diagnosis so as to appropriately treat the patient and plan the follow-up. Cancer screening

詳細技術說明: The conception of the future product is to offer a two-step test: After recognising a suspicious event on ultrasonography, the resident urologist is able to test the urine of the patient with a test-strip or ELISA which combines both markers. If the kidney tumor is benign (Oncocytoma), Vim3 is detectable. In case of positive Mxi-2 detection, the tumor is malignant (RCC). No staining indicates no kidney tumor is present. After the surgery the result will be confirmed in the removed tumor tissue.

分類: - international:
C12Q1/68; G01N33/574
- cooperative:
C12Q1/6886 (EP, US); G01N33/57438 (EP, US); C12Q2600/112 (US); C12Q2600/158 (EP)

欲了解更多信息，請點擊這裡